A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

BACKGROUND: Cabazitaxel, a semisynthetic microtubule inhibitor, has shown antitumour activity in models resistant to paclitaxel and docetaxel, and it has been approved for the treatment of docetaxel-resistant prostate cancer. We investigated its activity in patients with advanced non-small-cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotsakis, A, Matikas, A, Koinis, F, Kentepozidis, N, Varthalitis, I I, Karavassilis, V, Samantas, Ep, Katsaounis, P, Dermitzaki, E K, Hatzidaki, D, Mavroudis, D, Georgoulias, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046219/
https://www.ncbi.nlm.nih.gov/pubmed/27607471
http://dx.doi.org/10.1038/bjc.2016.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046219/
https://www.ncbi.nlm.nih.gov/pubmed/27607471
http://dx.doi.org/10.1038/bjc.2016.281

Ejemplares similares